Key Takeaways
Procept Biorobotics reported Q1 2026 gross margin of 65%, a 440-basis-point improvement from Q4 2025 and the highest in company history, driven by pricing discipline and improved operational leverage. While the tape focused on commercial realignment headwinds—flat quarter-over-quarter procedures and handpiece sales below the 1:1 target—management's confidence in the full-year $390–410M revenue guide (27–33% growth) and 65% gross margin target rests on this margin inflection, which de-risks the trajectory even if procedure growth moderates. The stock sold off 5.7% on the earnings day despite the margin beat and raised guidance, suggesting the market has not yet priced the pricing power and operational leverage embedded in the margin trajectory.
Filing Snapshot
Procept Biorobotics (PRCT) reported Q1 2026 earnings on April 29, 2026, with total revenue of $83.1 million (20% YoY growth) and gross margin of 65%. The company reaffirmed its full-year 2026 revenue guidance of $390–410 million (27–33% growth) and full-year gross margin target of 65%, with management citing improved pricing discipline and operational excellence. The differential: the tape narrative centered on commercial realignment disruption (sales force restructuring, flat procedures, handpiece sales below 1:1 ratio), but the real story is the margin inflection that de-risks the full-year guide despite near-term growth headwinds.
Tape Read
The morning tape and sell-side notes focused on the commercial realignment as a near-term headwind. Q1 U.S. procedures were approximately 12,200, flat quarter-over-quarter, attributed to sales force transition and normal seasonality. Handpiece sales were approximately 95% of procedures (below the historical 1:1 ratio), signaling inventory normalization and disruption from the commercial restructuring. Management acknowledged the transition phase: "handpiece sales disruption from sales force realignment, transition phase with re-establishing account relationships." The stock closed down 5.7% on April 29 and 4.4% on April 28, despite the earnings beat and raised guidance, suggesting the market was pricing the commercial realignment as a material risk to the full-year trajectory.
Filing Read: The Margin Inflection
The buried detail is the gross margin inflection. Q1 2026 gross margin of 65% represents a 440-basis-point sequential improvement from Q4 2025 (60.6%) and a 120-basis-point year-over-year improvement from Q1 2025 (63.8%). This inflection was driven by three factors disclosed in the 8-K and earnings call: (1) pricing discipline — management established "price discipline with U.S. hydro system average selling price at an all-time high" of approximately $485,000 in Q1, with guidance for $450–460,000 for the remainder of the year; (2) handpiece pricing — the company increased handpiece list prices on January 1, 2026, and expects handpiece pricing to be a "meaningful revenue tailwind" in 2026; and (3) operational leverage — improved overhead absorption and favorable revenue mix of U.S. handpieces. The 8-K guidance slide explicitly targets 65% gross margin for full-year 2026 and 68–70% for 2027, with a clear path to profitability driven by "HP revenue mix will be meaningful tailwind to corporate gross margin expansion." This margin inflection de-risks the full-year guide because even if procedure growth moderates (management guided Q2 revenue to $91–95M, or 15–20% growth, below the full-year 27–33% range), the pricing power and margin expansion offset the near-term growth headwinds.
Verification Numbers
Q1 2026 gross margin of 65% is disclosed in the earning call summary and 8-K guidance. Full-year 2026 gross margin target of 65% is confirmed in the 8-K Item 8.01 and earnings call. U.S. hydro system ASP of approximately $485,000 in Q1 is disclosed in the earnings call, with guidance for $450–460,000 for the remainder of the year. Handpiece pricing increase on January 1, 2026, is disclosed in the 8-K guidance slide. Full-year 2026 revenue guidance of $390–410M (27–33% growth) is confirmed in the 8-K and earnings call. Analyst consensus as of April 29 is 5 Buy, 2 Hold, 1 Sell, with a consensus price target of $29.43, suggesting the market has not yet fully priced the margin inflection and pricing power.
What Would Invalidate
The thesis breaks if: (1) Q2 or Q3 gross margin falls below 64%, signaling that pricing discipline is not holding or that operational leverage is reversing; (2) full-year procedure growth falls below 39% (the low end of guidance), indicating that the commercial realignment disruption is more severe than management expects; or (3) management cuts the full-year revenue or margin guidance in the next 10-Q or 8-K, signaling that the pricing power or operational leverage is not sustainable. The next earnings call (Q2 2026, expected in late July or early August) will be the key test of whether the margin inflection is durable or a one-quarter anomaly.